2.5.2025 23:06:46 CEST | Thor Medical ASA | Additional regulated information required to be disclosed under the laws of a member state

Oslo, Norway, 2 May 2025

Reference is made to the stock exchange announcement made by Thor Medical ASA (the "Company") the Company on 2 May 2025 regarding the grant of restricted share units ("RSU") to members of the board of directors.

Primary insider notifications pursuant to the market abuse regulation article 19 are attached hereto. This information is required to be disclosed under Section 5-12 of the Securities Trading Act.

CONTACTS

Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

Attachments

• Download announcement as PDF.pdf
• Jens Gisle Schnelle - Primary insider notifications.pdf
• Mimi K Berdal - Primary insider notifications.pdf
• Thomas Ramdahl - Primary insider notifications.pdf